2.5 years on topical finasteride (0.1% fin + 7% min): hair success and why I stopped Finasteride/Dutasteride 1/21/2026
Topical finasteride with minoxidil effectively stabilized and thickened hair but caused side effects like brain fog, reduced libido, and emotional flattening, leading to discontinuation. The user switched to a new regimen including minoxidil, KX-826, and other treatments, noting improvements in libido and vivid dreams after stopping finasteride.
View this post in the Community →
Similar Community Posts Join
6 / 1000+ resultscommunity Received Kintor’s KX-826 Today
A user received Kintor’s KX-826/Pyrilutamide and shared initial impressions, noting concerns about the product's labeling and marketing. Other users discussed the legitimacy of the product, its effectiveness, and compared it to other treatments like Minoxidil and Finasteride.
community 6 Month Update as a Bad Diffuse Thinner
A user shared their 6-month update on hair loss treatment, using daily Dutasteride, oral and topical Minoxidil, Ketoconazole shampoo, topical Finasteride, dermastamping, and PRP treatments. They reported improved hair quality but no significant regrowth or density increase, and plan to continue the regimen for another year before considering a hair transplant.
community Do you believe there will be a game changing treatment in the next 10 years?
Users discuss potential game-changing hair loss treatments in the next 10 years. Some mention KX-826, SCUBE3, and stem cells as promising options, while others express doubt due to past disappointments and lack of focused research.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community KX-826: Long-Term Safety Results are out!
KX-826 initially improves hair growth but declines after 24 weeks, with mild itching as a side effect. Combining it with minoxidil and finasteride may improve results, but long-term effectiveness is uncertain.
community Binding affinity of pyrilutamide!
Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.
Related Research
6 / 1000+ results
research A Decade of Progress in Androgenetic Alopecia Management: Emerging Therapies and Multimodal Strategies
Androgenetic alopecia treatments are becoming more personalized and include new therapies like topical antiandrogens and regenerative strategies.
research Androgenetic Alopecia: Therapy Update
There are many treatments for common hair loss, but more trials are needed to decide which are best.
research Recent Advances in Drug Development for Hair Loss
New treatments for hair loss show promise with advanced therapies and better targeting.
research Topical Solutions for Androgenetic Alopecia: Evaluating Efficacy and Safety
Topical treatments for hair loss can be effective but need careful safety evaluation.
research The 100 Most Cited Articles in Androgenetic Alopecia: A Bibliometric Analysis
Recent research on androgenetic alopecia focuses on optimizing treatments, with promising new therapies emerging.
research Focused Review on Metal Nanoparticles in Hair Regeneration and Alopecia: Insights into Mechanisms, Assessment Techniques, Toxicity, Regulatory and Intellectual Property Perspectives
Metal nanoparticles show promise for treating hair loss but need more research to ensure safety.